Therapeutic Targets for Management of Periodontitis and Diabetes

Author(s): Corneliu Sima, Thomas E. Van Dyke

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 15 , 2016

Become EABM
Become Reviewer
Call for Editor


The increasing incidence of diabetes mellitus (DM) and chronic periodontitis (CP) worldwide imposes a rethinking of individualized therapy for patients with both conditions. Central to bidirectional links between DM and CP is deregulated systemic inflammation and dysfunctional immune responses to altered-self and non-self. Control of blood glucose levels and metabolic imbalances associated with hyperglycemia in DM, and disruption of pathogenic subgingival biofilms in CP are currently the main therapeutic approaches for these conditions. Mounting evidence suggests the need to integrate immune modulatory therapeutics in treatment regimens that address the unresolved inflammation associated with DM and CP. The current review discusses the pathogenesis of DM and CP with emphasis on deregulated inflammation, current therapeutic approaches and the novel pro-resolution lipid mediators derived from -3 polyunsaturated fatty acids.

Keywords: Diabetes mellitus, periodontitis, inflammation, lipid mediators, pro-resolution therapeutics.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Page: [2216 - 2237]
Pages: 22
DOI: 10.2174/1381612822666160216150338

Article Metrics

PDF: 95